Page 4 - Anjali Singh

Union Budget 2026-27: Over ₹1 trillion earmarked for the nation's health

Biopharma Shakti initiative to tackle burden of non-communicable diseases, turn India into global, innovation-led hub

Budget 2026: Govt to set up 5 medical tourism hubs, train 150K caregivers

Finance Minister Nirmala Sitharaman announced measures in the Union Budget 2026-27 to boost medical tourism, including support for five regional hubs in partnership with states and the private sector

Sun Pharma Q3FY26 profit rises 16% on new launches, revenue climbs 13.5%

US generics remain under pressure while API revenues decline during the quarter

Glenmark Q3 profit rises 15% on strong market performance; Revenue up 15%

Pharma major reports double-digit growth in Q3 as India and North America lead performance, though profit and revenue declined sequentially

Bajaj Auto posts record Q3 revenue and profit as EVs fuel domestic growth

Two-wheeler maker records its highest-ever quarterly revenue and profit in Q3 FY26, aided by premium motorcycles, strong EV sales and a rebound in exports

Piramal Pharma flags early recovery signs in CDMO demand as Q3 loss widens

The company attributed the weaker performance largely to continued inventory destocking in one of its large on-patent commercial products, affecting its CDMO business

India-EU free trade pact set to redraw growth map for Indian CDMOs

India-EU FTA could transform India's CDMO sector by cutting pharma tariffs, easing regulations and deepening Indian integration into Europe's drug supply chains

NITI Aayog calls for tighter norms to fix India's waste tyre recycling gaps

A new NITI Aayog assessment said tyre production is projected to double over the next decade, significantly increasing the volume of discarded tyres

E2W companies seek PM E-Drive subsidy extension beyond March 2026

Industry executives say incentives continue to play a role in easing upfront cost concerns for price-sensitive buyers

First wave of generic semaglutide approvals opens up India market

India has entered the first phase of generic semaglutide approvals, with CDSCO clearing multiple formulations for obesity and diabetes, paving the way for lower-cost GLP-1 therapies

Syngene downgrades its revenue guidance by 5% on Librela inventory impact

Syngene trims FY26 revenue guidance by up to 5% as inventory correction for veterinary drug Librela hits profits, even as core research and CDMO business grows

Cipla Q3 results: Net profit slumps 57% to ₹675 crore on US supply issues

Bets on respiratory product launches and peptides for growth

Syngene International Q3 net profit plunges 89%, revenue slips 3%

Librela inventory correction and one-time labour code costs weigh on earnings

Medical emergencies drive urban Indians to personal loans, says study

Rising medical costs and insurance gaps are pushing more urban Indians to take personal loans for healthcare, with reliance highest in Tier-I cities, a Paisabazaar study shows

Doctors warn of rising health and financial risks as air quality worsens

Study of doctors flags growing concern over worsening air quality in Indian cities, linking high AQI levels to chronic illnesses, rising healthcare costs and poor financial preparedness among patients

Toyota enters India's electric vehicle market with Urban Cruiser Ebella

Toyota Kirloskar Motor enters India's EV market with the Urban Cruiser Ebella, a born-electric SUV developed with Maruti Suzuki, as it pursues a multi-technology electrification strategy

Lamborghini posted record 2025 deliveries but India sales declined

Lamborghini delivered a record 10,747 vehicles globally in 2025, crossing the 10,000 mark for the first time, though sales in India slipped marginally amid uneven market conditions

Southern states hold the steering wheel in India's ePV transition

India's electric passenger vehicle registrations have surged over five years, with southern states consistently contributing about one-third of volumes

Sun Pharma terms $10 billion Organon acquisition reports 'speculative'

Sun Pharmaceutical said reports of a $10 billion acquisition of US-based Organon are speculative, adding there is no material information requiring disclosure to exchanges

FDA observation to hit Lanreotide supply; Cipla may face earnings risk

Cipla said supplies of its key US drug Lanreotide will remain constrained after its manufacturing partner paused production following USFDA observations